Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713855 | 1.00 | PDE4B (0.74) | PDE4B | |
| SCHEMBL30352597 | 1.00 | PDE4B (0.74) | PDE4B | |
| SCHEMBL30352669 | 1.00 | PDE4B (0.74) | PDE4B | |
| SCHEMBL22713940 | 0.85 | PDE4B (1.00) | PDE4B | |
| SCHEMBL22713941 | 0.85 | PDE4B (1.00) | PDE4B | |
| SCHEMBL30352704 | 0.84 | PDE4B (0.67) | PDE4B | |
| SCHEMBL22713953 | 0.84 | PDE4B (0.67) | PDE4B | |
| SCHEMBL22713948 | 0.84 | PDE4B (0.67) | PDE4B | |
| SCHEMBL22713859 | 0.80 | PDE4B (0.73) | PDE4B | |
| SCHEMBL22714011 | 0.80 | PDE4B (0.73) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777979-B1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| CN-110407741-B | Anti-inflammatory compound and preparation and application thereof | 启元生物(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2022-09-13 | — | — | US | disclosed |
| EP-3777979-A1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | Vivavision Biotech, Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | PDE4B, PDE4A, PDE7A | PDE4B 1/4885 |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | PDE4B, PDE4A, PDE7A | PDE4B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.